Loading...
XPAR
ERF
Market cap9.66bUSD
Apr 08, Last price  
47.13EUR
1D
2.46%
1Q
-2.22%
Jan 2017
-88.36%
Name

Eurofins Scientific SE

Chart & Performance

D1W1MN
P/E
21.66
P/S
1.27
EPS
2.18
Div Yield, %
1.06%
Shrs. gr., 5y
0.90%
Rev. gr., 5y
8.78%
Revenues
6.95b
+6.70%
233,107,000367,990,000491,773,000632,759,000640,073,000680,333,000828,934,0001,043,963,0001,225,572,0001,410,227,0001,950,074,0002,536,608,0002,971,417,0003,781,148,0004,562,800,0005,438,800,0006,717,700,0006,712,100,0006,514,600,0006,951,000,000
Net income
406m
+30.97%
12,393,00017,508,00017,638,00017,710,000-11,285,00023,400,00055,407,00065,924,00072,180,00079,104,00087,316,000173,997,000216,771,000223,900,000195,200,000539,400,000782,600,000610,200,000310,300,000406,400,000
CFO
1.32b
+29.57%
25,488,00030,178,00039,569,00060,036,00064,337,00084,937,000110,321,000134,161,000169,338,000212,173,000291,146,000371,843,000405,122,000543,895,000677,900,0001,223,500,0001,509,800,0001,136,300,0001,017,900,0001,318,900,000
Dividend
Jul 03, 20240.5 EUR/sh
Earnings
Jul 22, 2025

Profile

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
URL
https://www.eurofins.com/
IPO date
Oct 24, 1997
Employees
62,000
Domiciled in
LU
Incorporated in
LU

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,951,000
6.70%
6,514,600
-2.94%
6,712,100
-0.08%
Cost of revenue
2,238,800
5,894,200
2,227,000
Unusual Expense (Income)
NOPBT
4,712,200
620,400
4,485,100
NOPBT Margin
67.79%
9.52%
66.82%
Operating Taxes
149,100
115,500
174,200
Tax Rate
3.16%
18.62%
3.88%
NOPAT
4,563,100
504,900
4,310,900
Net income
406,400
30.97%
310,300
-49.15%
610,200
-22.03%
Dividends
(95,600)
(191,900)
(192,100)
Dividend yield
1.00%
1.64%
1.44%
Proceeds from repurchase of equity
(271,700)
(47,800)
(1,200)
BB yield
2.83%
0.41%
0.01%
Debt
Debt current
478,800
601,000
213,700
Long-term debt
3,739,000
3,904,300
3,639,400
Deferred revenue
1,000,000
Other long-term liabilities
152,400
1,194,000
214,900
Net debt
3,603,900
3,200,500
3,282,900
Cash flow
Cash from operating activities
1,318,900
1,017,900
1,136,300
CAPEX
(453,600)
(478,100)
(660,200)
Cash from investing activities
(846,500)
(681,100)
(855,900)
Cash from financing activities
(1,089,500)
495,800
(311,300)
FCF
3,846,900
292,200
3,906,800
Balance
Cash
613,900
1,221,200
486,600
Long term investments
83,600
83,600
Excess cash
266,350
979,070
234,595
Stockholders' equity
2,739,900
4,192,300
4,282,500
Invested Capital
8,881,150
8,278,830
7,616,705
ROIC
53.18%
6.35%
60.13%
ROCE
50.90%
6.62%
56.17%
EV
Common stock shares outstanding
194,500
197,900
199,000
Price
49.31
-16.40%
58.98
-12.05%
67.06
-38.36%
Market cap
9,590,795
-17.83%
11,672,142
-12.54%
13,344,940
-38.86%
EV
13,240,495
14,932,542
16,696,740
EBITDA
5,309,100
1,185,400
4,989,500
EV/EBITDA
2.49
12.60
3.35
Interest
150,800
129,400
105,600
Interest/NOPBT
3.20%
20.86%
2.35%